| Literature DB >> 22919430 |
Gilberto de Araujo Pereira1, Francisco Louzada, Valdirene de Fátima Barbosa, Márcia Maria Ferreira-Silva, Helio Moraes-Souza.
Abstract
We propose a new general Bayesian latent class model for evaluation of the performance of multiple diagnostic tests in situations in which no gold standard test exists based on a computationally intensive approach. The modeling represents an interesting and suitable alternative to models with complex structures that involve the general case of several conditionally independent diagnostic tests, covariates, and strata with different disease prevalences. The technique of stratifying the population according to different disease prevalence rates does not add further marked complexity to the modeling, but it makes the model more flexible and interpretable. To illustrate the general model proposed, we evaluate the performance of six diagnostic screening tests for Chagas disease considering some epidemiological variables. Serology at the time of donation (negative, positive, inconclusive) was considered as a factor of stratification in the model. The general model with stratification of the population performed better in comparison with its concurrents without stratification. The group formed by the testing laboratory Biomanguinhos FIOCRUZ-kit (c-ELISA and rec-ELISA) is the best option in the confirmation process by presenting false-negative rate of 0.0002% from the serial scheme. We are 100% sure that the donor is healthy when these two tests have negative results and he is chagasic when they have positive results.Entities:
Mesh:
Year: 2012 PMID: 22919430 PMCID: PMC3419444 DOI: 10.1155/2012/487502
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Settings used for the simulation of artificial data.
| Covariate ( | ||||
|---|---|---|---|---|
|
|
| |||
| Stratum |
|
| ||
| Parameter | 1 | 2 | 1 | 2 |
|
| 0.10 | 0.60 | 0.30 | 0.90 |
|
| ||||
| Se1| | 0.50 | 0.60 | ||
| Se2| | 0.75 | 0.80 | ||
| Se3| | 0.90 | 0.95 | ||
|
| ||||
| Sp1| | 0.60 | 0.50 | ||
| Sp2| | 0.80 | 0.75 | ||
| Sp3| | 0.95 | 0.90 | ||
ξ : prevalence rates in vth stratum to covariate W; Se and Sp: sensitivity and specificity of kth test in vth stratum to covariate W.
Selection of models based on the AIC, BIC, and DIC.
| Model |
| AIC | BIC | DIC |
|---|---|---|---|---|
| SSensI: ( | 7 | 1108483.0 | 1108514.0 | 1125999.0 |
| SSensII: ( | 8 | 1069892.0 | 1069927.0 | 1125833.0 |
| SSensIII: ( | 14 | 308389.8 | 308451.5 | 309236.4 |
| SSensIV: ( | 16 | 167959.7 | 168030.1 | 46198.1 |
p: number of parameters in the model.
Location and scale hyperparameter values of the normal prior distributions (6) for model ModII (L = 6, M = 3, V = 2).
| Sensitivity |
|
|
|
| ||
|
|
| |
|
| ||
| Specificity |
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
| ||
| Prevalence |
|
|
|
|
| |
|
|
| |
c = 1: AGE-age (≤30, >30 years); c = 2: GEN-gender (male, female); c = 3: RFE-presence of at least two of three risk factors epidemiological (origin from an endemic region, contact with the vector transmitting the disease and family history of Chagas' disease); Stratum I (v = 1) donors with negative or positive serology and Stratum II (v = 2) with inconclusive serology in the screening test; γ 1: effect of the cth covariate on the sensitivity of kth test; γ 0: effect of the cth covariate on the specificity of kth test; γ : effect of the cth covariate on disease prevalence in vth stratum.
Selection of models based on the AIC, BIC, and DIC.
| Model |
| AIC | BIC | DIC |
|---|---|---|---|---|
| ModI: ( | 52 | 813.09 | 943.08 | 719.88 |
| ModII: ( | 56 | 511.39 | 651.38 | 402.03 |
| ModIII: ( | 60 | 756.49 | 906.48 | 638.13 |
p: number of parameters in the model.
Summary of the posterior probability estimates obtained for the parameters that measure the effect of the cth covariate on the sensitivity and specificity of kth test and on disease prevalence in vth stratum, using model ModII (L = 6, M = 3, V = 2).
| Sensitivity ( | Specificity ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Test | Parameter | Mean |
|
| Test | Parameter | Mean |
|
|
| ELISA |
| 5.91 | 3.03 | 8.79 | ELISA |
| 3.47 | 1.80 | 5.10 |
|
| 0.50 | 0.02 | 0.96 |
| −1.92 | −2.79 | −0.94 | ||
|
| 0.51 | 0.03 | 1.00 |
| −2.10 | −2.90 | −1.14 | ||
|
| 0.50 | −0.01 | 0.96 |
| −2.12 | −2.89 | −1.11 | ||
| IIF |
| 5.79 | 2.89 | 8.82 | IIF |
| 6.51 | 3.01 | 9.73 |
|
| 0.51 | 0.04 | 0.99 |
| −2.08 | −2.89 | −1.02 | ||
|
| 0.49 | 0.00 | 0.98 |
| −2.12 | −2.89 | −1.16 | ||
|
| 0.50 | 0.02 | 1.00 |
| −2.12 | −2.89 | −1.10 | ||
|
| |||||||||
| IHA |
| 5.77 | 2.76 | 8.65 | IHA |
| 6.56 | 2.88 | 10.01 |
|
| 0.51 | 0.03 | 0.99 |
| −2.10 | −2.86 | −1.05 | ||
|
| 0.49 | 0.01 | 0.97 |
| −2.11 | −2.91 | −1.11 | ||
|
| 0.51 | 0.04 | 0.98 |
| −2.12 | −2.85 | −1.15 | ||
|
| |||||||||
| HEMO |
| −0.50 | −0.78 | −0.22 | HEMO |
| 100 | 100 | 100 |
|
| 0.38 | −0.06 | 0.84 |
| 0 | 0 | 0 | ||
|
| 0.45 | 0.02 | 0.89 |
| 0 | 0 | 0 | ||
|
| 0.31 | −0.12 | 0.74 |
| 0 | 0 | 0 | ||
|
| |||||||||
| c-ELISA |
| 5.76 | 2.87 | 8.75 | c-ELISA |
| 2.00 | 1.01 | 2.97 |
|
| 0.51 | 0.02 | 1.00 |
| −1.91 | −2.77 | −0.94 | ||
|
| 0.49 | 0.04 | 0.97 |
| −2.11 | −2.90 | −1.07 | ||
|
| 0.49 | 0.00 | 0.98 |
| −2.08 | −2.85 | −1.11 | ||
|
| |||||||||
| rec-ELISA |
| 5.72 | 2.82 | 8.70 | rec-ELISA |
| 6.50 | 3.16 | 10.03 |
|
| 0.21 | −0.18 | 0.74 |
| −2.08 | −2.87 | −1.05 | ||
|
| 0.54 | 0.07 | 1.00 |
| −2.09 | −2.90 | −1.03 | ||
|
| 0.46 | −0.05 | 0.97 |
| −2.11 | −2.88 | −1.09 | ||
|
| |||||||||
| Prevalence ( | |||||||||
| Stratum | Parameter | Mean |
|
| Stratum | Parameter | Mean |
|
|
|
| |||||||||
| I |
| 0.50 | 0.21 | 0.81 | II |
| −2.01 | −2.92 | −1.03 |
|
| 0.51 | 0.11 | 0.91 |
| 0.41 | −0.04 | 0.84 | ||
|
| 0.43 | 0.00 | 0.85 |
| 0.49 | 0.03 | 0.94 | ||
|
| 0.69 | 0.28 | 1.12 |
| 0.43 | −0.02 | 0.89 | ||
P2.5%: 2.5th percentile; P97.5%: 97.5th percentile; ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofluorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional ELISA using the Biomanguinhos kit; rec-ELISA (recombinant ELISA using the Biomanguinhos kit and CRA and FRA antigens); c = 1: AGE-age (≤30, >30 years); c = 2: GEN-gender (male, female); c = 3: RFE-presence of at least two of three risk factors epidemiological (origin from an endemic region, contact with the vector transmitting the disease, and family history of Chagas' disease); Stratum I (v = 1) donors with negative or positive serology and Stratum II (v = 2) with inconclusive serology in the screening test; γ 1: effect of the cth covariate on the sensitivity of kth test; γ 0: effect of the cth covariate on the specificity of kth test; γ : effect of the cth covariate on disease prevalence in vth stratum.
Sensitivity and specificity of the six diagnostic tests according to each level of the three covariates obtained with model ModII (L = 6, M = 3, V = 2).
| Sensitivity | Specificity | ||||||
|---|---|---|---|---|---|---|---|
| Test | Covariates | Mean |
|
| Mean |
|
|
| ELISA | General | 0.9925 | 0.9537 | 0.9998 | 0.9589 | 0.8577 | 0.9940 |
| AGE- ≤ 30 years | 0.9877 | 0.9261 | 0.9998 | 0.9919 | 0.9614 | 0.9993 | |
| AGE- > 30 years | 0.9953 | 0.9704 | 0.9999 | 0.7952 | 0.5007 | 0.9647 | |
| GEN-male | 0.9876 | 0.9255 | 0.9998 | 0.9941 | 0.9771 | 0.9994 | |
| GEN-female | 0.9953 | 0.9707 | 0.9999 | 0.7604 | 0.3585 | 0.9609 | |
| RFE-no | 0.9878 | 0.9252 | 0.9998 | 0.9941 | 0.9740 | 0.9994 | |
| RFE-yes | 0.9952 | 0.9713 | 0.9999 | 0.7592 | 0.3625 | 0.9566 | |
|
| |||||||
| IIF | General | 0.9913 | 0.9472 | 0.9999 | 0.9936 | 0.9529 | 0.9999 |
| AGE- ≤ 30 years | 0.9856 | 0.9112 | 0.9998 | 0.9987 | 0.9928 | 1 | |
| AGE- > 30 years | 0.9945 | 0.9677 | 0.9999 | 0.9605 | 0.7202 | 0.9996 | |
| GEN-male | 0.9860 | 0.9128 | 0.9998 | 0.9991 | 0.9940 | 1 | |
| GEN-female | 0.9943 | 0.9650 | 0.9999 | 0.9559 | 0.6674 | 0.9996 | |
| RFE-no | 0.9856 | 0.9171 | 0.9998 | 0.9991 | 0.9937 | 1 | |
| RFE-yes | 0.9945 | 0.9650 | 0.9999 | 0.9561 | 0.6845 | 0.9996 | |
|
| |||||||
| IHA | General | 0.9912 | 0.9406 | 0.9998 | 0.9930 | 0.9468 | 1 |
| AGE- ≤ 30 years | 0.9852 | 0.9038 | 0.9997 | 0.9988 | 0.9924 | 1 | |
| AGE- > 30 years | 0.9945 | 0.9667 | 0.9999 | 0.9588 | 0.7063 | 0.9997 | |
| GEN-male | 0.9858 | 0.9087 | 0.9997 | 0.9990 | 0.9932 | 1 | |
| GEN-female | 0.9943 | 0.9638 | 0.9999 | 0.9570 | 0.6813 | 0.9997 | |
| RFE-no | 0.9855 | 0.8989 | 0.9997 | 0.9990 | 0.9920 | 1 | |
| RFE-yes | 0.9945 | 0.9619 | 0.9999 | 0.9560 | 0.6992 | 0.9997 | |
|
| |||||||
| HEMO | General | 0.3782 | 0.3140 | 0.4442 | 1 | 1 | 1 |
| AGE- ≤ 30 years | 0.2959 | 0.1936 | 0.4110 | 1 | 1 | 1 | |
| AGE- > 30 years | 0.4715 | 0.3537 | 0.6006 | 1 | 1 | 1 | |
| GEN-male | 0.4014 | 0.3328 | 0.4677 | 1 | 1 | 1 | |
| GEN-female | 0.4467 | 0.3511 | 0.5396 | 1 | 1 | 1 | |
| RFE-no | 0.3116 | 0.2077 | 0.4275 | 1 | 1 | 1 | |
| RFE-yes | 0.4526 | 0.3317 | 0.5823 | 1 | 1 | 1 | |
|
| |||||||
| c-ELISA | General | 0.9911 | 0.9461 | 0.9998 | 0.8703 | 0.7333 | 0.9513 |
| AGE- ≤ 30 years | 0.9853 | 0.9055 | 0.9997 | 0.9747 | 0.9179 | 0.9951 | |
| AGE- > 30 years | 0.9944 | 0.9630 | 0.9999 | 0.5181 | 0.2540 | 0.8044 | |
| GEN-male | 0.9861 | 0.9189 | 0.9997 | 0.9795 | 0.9360 | 0.9954 | |
| GEN-female | 0.9941 | 0.9625 | 0.9999 | 0.4744 | 0.1936 | 0.7790 | |
| RFE-no | 0.9858 | 0.9175 | 0.9997 | 0.9791 | 0.9345 | 0.9955 | |
| RFE-yes | 0.9942 | 0.9605 | 0.9999 | 0.4805 | 0.1946 | 0.7862 | |
|
| |||||||
| rec-ELISA | General | 0.9908 | 0.9435 | 0.9998 | 0.9941 | 0.9591 | 1 |
| AGE- ≤ 30 years | 0.9886 | 0.9294 | 0.9998 | 0.9990 | 0.9939 | 1 | |
| AGE- > 30 years | 0.9923 | 0.9558 | 0.9999 | 0.9606 | 0.7286 | 0.9996 | |
| GEN-male | 0.9848 | 0.9129 | 0.9997 | 0.9991 | 0.9940 | 1 | |
| GEN-female | 0.9942 | 0.9659 | 0.9999 | 0.9588 | 0.6933 | 0.9997 | |
| RFE-no | 0.9851 | 0.9073 | 0.9997 | 0.9992 | 0.9944 | 1 | |
| RFE-yes | 0.9941 | 0.9646 | 0.9999 | 0.9590 | 0.7259 | 0.9997 | |
P2.5%: 2.5th percentile; P97.5%: 97.5th percentile; ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofluorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional ELISA using the Biomanguinhos kit; rec-ELISA (recombinant ELISA using the Biomanguinhos kit and CRA and FRA antigens); AGE-age (≤30, >30 years); GEN-gender (male, female); RFE-presence of at least two of three risk factors epidemiological (origin from an endemic region, contact with the vector transmitting the disease, and family history of Chagas' disease).
Prevalence rates of Chagas' disease in each of the three strata according to each level of the three covariates obtained with model ModII (L = 6, M = 3, V = 2).
| Prevalence | ||||
|---|---|---|---|---|
| Stratum | Covariates | Mean |
|
|
| I | General | 0.6215 | 0.5516 | 0.6915 |
| AGE ≤ 30 years | 0.4975 | 0.3723 | 0.6237 | |
| AGE > 30 years | 0.7298 | 0.6277 | 0.8136 | |
| GEN-male | 0.5169 | 0.3899 | 0.6380 | |
| GEN-female | 0.7138 | 0.6006 | 0.8054 | |
| RFE-no | 0.4527 | 0.3238 | 0.5729 | |
| RFE-yes | 0.7634 | 0.6619 | 0.8471 | |
|
| ||||
| II | General | 0.1277 | 0.0512 | 0.2633 |
| AGE ≤ 30 years | 0.0909 | 0.0310 | 0.2022 | |
| AGE > 30 years | 0.1811 | 0.0693 | 0.3700 | |
| GEN-male | 0.0845 | 0.0276 | 0.2035 | |
| GEN-female | 0.1935 | 0.0705 | 0.3837 | |
| RFE-no | 0.0895 | 0.0292 | 0.1987 | |
| RFE-yes | 0.1839 | 0.0718 | 0.3770 | |
P2.5%: 2.5th percentile; P97.5%: 97.5th percentile; vth Stratum: I, II (donors with negative or positive serology and inconclusive in the screening test, resp.,); AGE-age (≤30, >30 years); GEN-gender (male, female); RFE-presence of at least two of three risk factors epidemiological (origin from an endemic region, contact with the vector transmitting the disease, and family history of Chagas' disease).